Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 14.05.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,290,059.63 28.600  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 14.05.2026 H2O LN IE000Q8F0M81 600,002.00 USD 11,925,015.76 19.875  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), the vertically integrated sports nutrition company that is elevating the game in health and wellness, today announced that CWENCH Hydration™ is now available at more than 170 Save-On-Foods locations across Western Canada. At launch, Save-On-Foods will be carrying an assortment of three of CWENCH Hydration’s most popular ready-to-drink (“RTD”) flavours – Blue...

IRVINE, Californie--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq : SBC) (« SBC Medical » ou la « société »), une organisation de services médicaux fournissant un soutien en matière de gestion dans un large éventail de domaines de la santé, a annoncé aujourd’hui ses résultats financiers pour le trimestre clos le 31 mars 2026. Chiffres du premier trimestre 2026 Le chiffre d’affaires total s’est élevé à 43 millions de dollars, soit une baisse de 9 % d’une année sur l’autre. Le...

VICTORIA, British Columbia--(BUSINESS WIRE)--Vecima will highlight its leadership at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS 4.0 access, and fiber solutions....

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée ― Publiés dans The Lancet Meiji Seika Pharma Co., Ltd. (siège social à Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui que les résultats de l’étude Integral-1, l’un des deux essais cliniques mondiaux d...

TURIN, Italy--(BUSINESS WIRE)--Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover....

TURIN, Italien--(BUSINESS WIRE)--Der Verwaltungsrat der Reply S.p.A. [EXM, STAR: REY] hat heute die Ergebnisse zum 31. März 2026 genehmigt. Seit Beginn des Jahres verzeichnete die Gruppe einen Konzernumsatz von 645,0 Millionen Euro – dies entspricht einer Steigerung von 6,2% gegenüber dem Vergleichszeitraum 2025. Alle Kennzahlen des Berichtszeitraums waren positiv. Im ersten Quartal 2026 betrug das konsolidierte EBITDA 112,0 Millionen Euro im Vergleich zu 105,3 Mio. im Jahr 2025 und entspricht...